Company / SG&A Expense
Phio Pharmaceuticals Corp. SG&A Expense History
FY2012-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$4.7M
FY2020
5-year range
$3.2M / $4.7M
FY2016-FY2020
Trend
+48.2%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 7 years, ranging from $3M in FY2013 to $6M in FY2012.
Based on SEC 10-K filings.
$5M in FY2020 with a 3-year CAGR of +9.2%.
Increased from $4M to $5M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +9.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +9.2%, indicating consistent growth.
- In FY2020, sg&a expense increased 48.2% year-over-year.
- Peak sg&a expense was recorded in FY2012.
- Lowest sg&a expense in the period was in FY2013.
Company context
Key Data Points
- Altman Z-Score -0.94 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $4.7M | +48.2% |
| FY2019 | $3.2M | -20.8% |
| FY2018 | $4.0M | +10.8% |
| FY2017 | $3.6M | +8.2% |
| FY2016 | $3.3M | +27.7% |
| FY2013 | $2.6M | -57.4% |
| FY2012 | $6.1M | - |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026